本文へ移動
cccskills
無料GitHub で公開

esa-pa-interpret-cct

Evaluates likelihood of primary aldosteronism by measuring plasma aldosterone suppression after oral captopril; normal suppression ≥30% makes PA unlikely, while lack of suppression with persistently suppressed plasma renin activity suggests PA. Use when assessing captopril challenge test (CCT) results for PA diagnosis in patients with positive aldosterone-to-renin ratio.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md3.1 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Interpret Captopril Challenge Test for PA

STEP 1 — Gather Information

  • Measure baseline plasma aldosterone concentration (PAC) and plasma renin activity (PRA) after seated/standing ≥1h, ensuring medications that affect the ARR (ACEi, ARBs, diuretics, MR antagonists) have been withdrawn per guideline Table 5.
  • Administer 25–50 mg captopril orally.
  • Draw blood for PAC, PRA, and cortisol at 0 h and 1–2 h post‑dose, keeping the patient seated during the interval.

STEP 2 — Rule In / Rule Out

  • If PAC decreases by ≥30% from baseline → PA unlikely (normal captopril response).
  • If PAC decreases by <30% and PRA remains suppressed → proceed to further stratification (possible PA).
  • If PAC decreases <30% but PRA is not suppressed → test indeterminate; consider alternative causes.

STEP 3 — Classify or Stratify

  • Among non‑suppressed cases, assess degree of aldosterone change:
    • Some suppression (0 % < ΔPAC < 30 %) → favors idiopathic adrenal hyperplasia (IAH).
    • No suppression or rise (ΔPAC ≤ 0 %) → favors aldosterone‑producing adenoma (APA).

STEP 4 — Decide

  • IAH‑suggestive pattern: consider saline infusion test or fludrocortisone suppression test for confirmation.
  • APA‑suggestive pattern: proceed to adrenal venous sampling for lateralization and potential unilateral adrenalectomy.
  • PA unlikely: investigate other causes of hypertension; do not pursue PA‑specific work‑up.

Clinical Guardrails / Mimics / Pitfalls

  • Do not interpret CCT if patient is on ACE inhibitors, ARBs, potassium‑wasting/sparing diuretics, MR antagonists, or NSAIDs without adequate washout (see Table 5).
  • Avoid in severe uncontrolled hypertension, hypokalemia, or congestive heart failure due to altered aldosterone dynamics.
  • False‑negative/equivocal results occur in up to ~30 % of cases; a non‑suppressive CCT alone does not confirm PA.
  • Ensure seated posture and adequate sodium intake; recumbent posture or sodium restriction can blunt the test response.

Concrete Clinical Example

A 58‑year‑old with resistant hypertension (BP 168/96 mm Hg) has baseline PAC 22 ng/dL, PRA 0.18 ng/mL/h. After 50 mg captopril, PAC falls to 16 ng/dL (27 % suppression) and PRA remains 0.09 ng/mL/h. Because suppression is <30 % and PRA stays suppressed, PA is suspected; subsequent AVS shows lateralization consistent with an aldosterone‑producing adenoma, leading to laparoscopic adrenalectomy.

Source: The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-4061

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する